The FDA approved a higher potency formulation of human rabies immune globulin (RIG), which provides a post-exposure prophylaxis (PEP) option that is easier for providers to administer as well as potentially more tolerable and effective for patients. The new formulation became available in May.
“Most people who die of rabies don’t receive any prophylaxis,” said Charles Rupprecht, VMD, MS, PhD, an expert technical advisor on rabies for the Pan American Health